Key result
Treated familial hypercholesterolemia is linked to ~33% lower MYLIP/IDOL levels than untreated disease.
Why the study?
PCSK9 and MYLIP/IDOL regulate cell-surface LDL receptors through different mechanisms in familial hypercholesterolemia. This study sought to compare serum PCSK9 and MYLIP/IDOL levels and lipid-profile parameters among healthy individuals, untreated FH patients, and treated FH patients.
Does lipid-lowering therapy alter serum PCSK9, MYLIP/IDOL, and lipid profile levels compared to no treatment or healthy controls in adults with familial hypercholesterolemia?
Cross-Sectional (n=90)
Yes
Does lipid-lowering therapy alter serum PCSK9, MYLIP/IDOL, and lipid profile levels compared to no treatment or healthy controls in adults with familial hypercholesterolemia?
Answers are grounded in this paper and cite their sources.
In Iraqi patients with familial hypercholesterolemia, lipid-lowering therapy is associated with lower serum MYLIP/IDOL and LDL-C levels alongside elevated PCSK9 levels compared to untreated patients, reflecting distinct regulatory responses of the LDL receptor pathway.
Background: Familial Hypercholesterolemia (FH), which is defined as a genetic disorder that causes a person to have high levels of LDL-C for their entire life, and therefore increases the risk of heart disease. Both PCSK9 and MYLIP/IDOL are proteins involved in regulating the amount of LDL receptors present on cell surfaces, but use different mechanisms. Objective: To compare the levels of serum PCSK9 and MYLIP/IDOL along with other lipid-profile parameters between healthy individuals, untreated FH patients, and treated FH patients. Methods: A cross-sectional study comparing three groups of individuals with different types of hypercholesterolemia was conducted among 90 subjects from Baghdad, Iraq (age 20-50 years): 30 normal control group members; 30 untreated familial hypercholesterolemia (FH) patients; and 30 treated FH patients. The serum PCSK9 and MYLIP/IDOL levels were determined via sandwich ELISA, while the concentrations of TC, TG, HDL-C, and LDL-C were evaluated through the use of a Roche Cobas Integra 400 analyzer. Results: There were differences among groups in all parameters measured (P<0.0001). The untreated FH group exhibited higher TC, TG, LDL-C, PCSK9, and MYLIP/IDOL than the control group; however, the untreated FH group also exhibited lower HDL-C than the control group. When compared to the untreated FH group, the treated FH group exhibited lower TC, LDL-C, and MYLIP/IDOL; conversely, the treated FH group also exhibited higher HDL-C and PCSK9 than the untreated FH group. After multiplicity adjustment, there were no differences between groups in terms of TG. The untreated FH group exhibited a positive correlation between MYLIP/IDOL and TC (r=0.607; adjusted P=0.0034). ROC analyses demonstrated that the highest area under curves (AUCs) were observed for LDL-C (1.000), TC (0.983), MYLIP/IDOL (0.982), and PCSK9 (0.921). Conclusion: There were significant lipid alterations in FH patients, which were accompanied by differences in PCSK9 and MYLIP/IDOL levels. Although treated FH patients had higher PCSK9 levels than untreated FH patients, their MYLIP/IDOL levels were lower. This may reflect different regulatory mechanisms for the LDL receptor pathway after treatment.
No takes yet. Share an insight, caveat, or question.
Ghufran Saad Nsaif (2026) conducted a cross-sectional in Familial Hypercholesterolemia (n=90). Lipid-lowering therapy in familial hypercholesterolemia vs. Untreated familial hypercholesterolemia and healthy controls was evaluated on Serum MYLIP/IDOL concentration (ng/L) (p=<0.0001). Treated familial hypercholesterolemia patients had lower MYLIP/IDOL and higher PCSK9 than untreated patients.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: